These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26546756)

  • 1. The impact of GnRH agonists in patients with endometriosis on prolactin and sex hormone levels: a pilot study.
    Marschalek J; Ott J; Husslein H; Kuessel L; Elhenicky M; Mayerhofer K; Franz MB
    Eur J Obstet Gynecol Reprod Biol; 2015 Dec; 195():156-159. PubMed ID: 26546756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.
    Nam HK; Kim HR; Rhie YJ; Lee KH
    J Korean Med Sci; 2017 Mar; 32(3):475-479. PubMed ID: 28145651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aromatase inhibitors prevent the estrogen rise associated with the flare effect of gonadotropins in patients treated with GnRH agonists.
    Bedaiwy MA; Mousa NA; Casper RF
    Fertil Steril; 2009 Apr; 91(4 Suppl):1574-7. PubMed ID: 18973892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of antimüllerian hormone in early maturing girls before, during, and after suppression with GnRH agonist.
    Hagen CP; Sørensen K; Anderson RA; Juul A
    Fertil Steril; 2012 Nov; 98(5):1326-30. PubMed ID: 22901847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pituitary function before, during, and after chronic gonadotropin-releasing hormone agonist therapy.
    Cedars MI; Steingold KA; Lu JH; Judd HJ; Meldrum DR
    Fertil Steril; 1992 Dec; 58(6):1104-7. PubMed ID: 1459255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.
    Su HI; Maas K; Sluss PM; Chang RJ; Hall JE; Joffe H
    J Clin Endocrinol Metab; 2013 Dec; 98(12):E1961-6. PubMed ID: 24081742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study comparing endocrinological and clinical effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
    Takeuchi H; Kobori H; Kikuchi I; Sato Y; Mitsuhashi N
    J Obstet Gynaecol Res; 2000 Oct; 26(5):325-31. PubMed ID: 11147718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and follicular fluid hormone levels during in vitro fertilization after short- or long-course treatment with a gonadotropin-releasing hormone agonist.
    Bo-Abbas YY; Martin KA; Liberman RF; Cramer DW; Barbieri RL
    Fertil Steril; 2001 Apr; 75(4):694-9. PubMed ID: 11287021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis.
    Regidor PA; Regidor M; Schmidt M; Ruwe B; Lübben G; Förtig P; Kienle E; Schindler AE
    Gynecol Endocrinol; 2001 Jun; 15(3):202-9. PubMed ID: 11447732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum anti-Mullerian hormone, prolactin and estradiol concentrations in infertile women with endometriosis.
    Pedachenko N; Anagnostis P; Shemelko T; Tukhtarian R; Alabbas L
    Gynecol Endocrinol; 2021 Feb; 37(2):162-165. PubMed ID: 33274686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
    Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
    Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles.
    Meyer L; Murphy LA; Gumer A; Reichman DE; Rosenwaks Z; Cholst IN
    Fertil Steril; 2015 Sep; 104(3):637-42. PubMed ID: 26149355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between FSH, inhibin B, anti-Mullerian hormone, and testosterone during long-term treatment with the GnRH-agonist histrelin in patients with prostate cancer.
    Eldar-Geva T; Liberty G; Chertin B; Fridmans A; Farkas A; Margalioth EJ; Spitz IM
    Eur J Endocrinol; 2010 Jan; 162(1):177-81. PubMed ID: 19820037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.
    Marder W; McCune WJ; Wang L; Wing JJ; Fisseha S; McConnell DS; Christman GM; Somers EC
    Gynecol Endocrinol; 2012 Aug; 28(8):624-7. PubMed ID: 22296584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of a gonadotropin-releasing hormone agonist and finasteride on idiopathic hirsutism.
    Bayhan G; Bahçeci M; Demirkol T; Ertem M; Yalinkaya A; Erden AC
    Clin Exp Obstet Gynecol; 2000; 27(3-4):203-6. PubMed ID: 11214952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential response of AMH to GnRH agonist among individuals: the effect on ovarian stimulation outcomes.
    Cai J; Liu L; Zheng J; Zhang L; Jiang X; Li P; Sha A; Ren J
    J Assist Reprod Genet; 2018 Mar; 35(3):467-473. PubMed ID: 29264688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
    Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
    Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on the endocrine system of long-term treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia.
    Eri LM; Haug E; Tveter KJ
    Scand J Clin Lab Invest; 1996 Jul; 56(4):319-25. PubMed ID: 8837238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin and its response to the luteinizing hormone-releasing hormone thyrotropin-releasing hormone test in patients with endometriosis before, during, and after treatment with danazol.
    Acién P; Lloret M; Graells M
    Fertil Steril; 1989 May; 51(5):774-80. PubMed ID: 2651165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.